Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Receivables (2021 - 2026)

Lucid Diagnostics filings provide 5 years of Receivables readings, the most recent being $643000.0 for Q4 2025.

  • On a quarterly basis, Receivables rose 1328.89% to $643000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $643000.0, a 1328.89% increase, with the full-year FY2025 number at $643000.0, up 1328.89% from a year prior.
  • Receivables hit $643000.0 in Q4 2025 for Lucid Diagnostics, up from $550000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $10.7 million in Q2 2023 to a low of $21000.0 in Q3 2023.
  • Median Receivables over the past 5 years was $373000.0 (2025), compared with a mean of $2.1 million.
  • Biggest five-year swings in Receivables: skyrocketed 3220.5% in 2022 and later tumbled 99.68% in 2023.
  • Lucid Diagnostics' Receivables stood at $1.9 million in 2021, then soared by 168.01% to $5.0 million in 2022, then tumbled by 99.1% to $45000.0 in 2023, then changed by 0.0% to $45000.0 in 2024, then soared by 1328.89% to $643000.0 in 2025.
  • The last three reported values for Receivables were $643000.0 (Q4 2025), $550000.0 (Q3 2025), and $373000.0 (Q2 2025) per Business Quant data.